Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models

  • Cook J
  • Sterman D
  • Singhal S
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • 5


    Citations of this article.


Surgical debulking of malignant mesothelioma (MM) ultimately fails due to local recurrence. Suramin, an inhibitor of extracellular growth factors (ECGFs), has demonstrated efficacy in the treatment of malignant mesothelioma in a small case series. Our goal was to study survival benefits and disease progression in several MM animal models treated with suramin as a potential agent for adjuvant therapy. In vitro growth of human (REN, I-45), rat (II-45) and murine (AB12) mesothelioma cell lines were measured with or without suramin exposure. Human and murine MM tumors were implanted subcutaneously into murine flanks or injected intraperitoneally (i.p.) into murine abdominal cavities. Dose and treatment schedules were optimized to reduce the rate of tumor progression and to improve survival curves. Suramin inhibited the in vitro growth of all cell lines, reaching statistical significance (P

Author-supplied keywords

  • Extracellular growth factors
  • Malignant mesothelioma
  • Suramin

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Judith W. Cook

  • Daniel H. Sterman

  • Sunil Singhal

  • W. Roy Smythe

  • Larry R. Kaiser

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free